According to studies on 3%-5% of NSCLC patients have mutation of BRAF 96 and some NSCLC patients have mutation of MEK, which could be used as the driving gene of NSCLC 97. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.